ENABLE-2 expands its portfolio with a British programme
Alistair Farley, Christopher Schofield, Diarmaid Hughes & Anders Karlén
The antibiotic platform ENABLE-2 welcomes a drug development programme from the Ineos Oxford Institute for antimicrobial research (IOI), based at the University of Oxford. "We are very happy that ENABLE-2 continues to consolidate its international presence with this promising programme," states Anders Karlén, Coordinator of ENABLE-2 and Professor at Uppsala University.
ENABLE-2, the antibacterial drug discovery platform coordinated by Uppsala University, has announced its support of a programme led by Professor Christopher Schofield and Dr. Alistair Farley of the Ineos Oxford Institute for antimicrobial research (IOI), based at the University of Oxford.
“Tackling a large global public health challenge such as AMR cannot be done in isolation. The development of new antibiotics requires extensive collaboration across scientific disciplines and across borders. We are therefore delighted to join the ENABLE-2 platform which brings together considerable expertise from across Europe in antibiotic medicinal chemistry. We look forward to progressing our series with the ENABLE-2 team.” says Professor Schofield.
The programme was previously part of the Innovative Medicines Initiative-funded project ENABLE, and currently holds a number of substances with the potential to form the basis of future antibiotics. In collaboration with ENABLE-2, the compounds will now be subject to further evaluation in order to identify the substances best suited for further development.
“Since ENABLE-2 was launched in 2021, it has attracted increasing interest outside of Sweden, and the majority of applications have been submitted from other European countries. We look forward to working with the team at the IOI to support their programme through the hit to lead stage of development,” states Anders Karlén, Coordinator of ENABLE-2 and Professor at Uppsala University.
More information
- The new programme focuses on a new class of broad spectrum metallo-beta-lactamase (MBL) inhibitors that restore the activity of carbapenems in multidrug-resistant Gram-negative Enterobacterales.
- ENABLE-2 is funded by the Swedish Research Council and the National Research Programme on Antibiotic Resistance.
- ENABLE-2 is accepting applications from researchers at publicly-funded universities and research institutes throughout Europe. For more information, please visit the ENABLE-2 website.
- ENABLE-2 is an antibacterial drug discovery platform with the expertise and resources to progress multiple programmes in parallel.
Contact
Anders Karlén
Coordinator, ENABLE-2
Professor, Uppsala University
Anders.Karlen@ilk.uu.se
Press enquiries & Information
Amy Buck
Communications Team
Ineos Oxford Institute for antimicrobial research
Amy.buck@chem.ox.ac.uk
Text: Magnus Alsne, Marie Olliver,
Photo: Mikael Wallerstedt and University of Oxford